Dynavax Technologies Corporation (DVAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) has a cash flow conversion efficiency ratio of 0.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.83 Million) by net assets ($534.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DVAX equity to assets ratio to measure how much of total assets are equity-financed.
Dynavax Technologies Corporation - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Dynavax Technologies Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Dynavax Technologies Corporation's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Dynavax Technologies Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dynavax Technologies Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telecom Argentina S.A
F:TEO
|
0.156x |
|
Ningbo Yunsheng Co Ltd
SHG:600366
|
-0.014x |
|
Sirius Real Estate Ltd
JSE:SRE
|
0.019x |
|
Astrana Health Inc
NASDAQ:ASTH
|
0.118x |
|
KPIT Technologies Limited
NSE:KPITTECH
|
0.112x |
|
Semapa
LS:SEM
|
0.059x |
|
Melia Hotels
MC:MEL
|
0.178x |
|
Guangdong Mingyang Electric Co. Ltd. A
SHE:301291
|
N/A |
Annual Cash Flow Conversion Efficiency for Dynavax Technologies Corporation (2002–2024)
The table below shows the annual cash flow conversion efficiency of Dynavax Technologies Corporation from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Dynavax Technologies Corporation market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $596.80 Million | $66.51 Million | 0.111x | -31.06% |
| 2023-12-31 | $622.07 Million | $100.56 Million | 0.162x | +49.76% |
| 2022-12-31 | $581.01 Million | $62.72 Million | 0.108x | -92.85% |
| 2021-12-31 | $222.37 Million | $335.53 Million | 1.509x | +196.00% |
| 2020-12-31 | $58.69 Million | $-92.25 Million | -1.572x | +89.25% |
| 2019-12-31 | $8.29 Million | $-121.25 Million | -14.626x | -602.51% |
| 2018-12-31 | $63.06 Million | $-131.30 Million | -2.082x | -435.95% |
| 2017-12-31 | $199.55 Million | $-77.52 Million | -0.388x | +67.63% |
| 2016-12-31 | $89.20 Million | $-107.05 Million | -1.200x | -142.56% |
| 2015-12-31 | $187.08 Million | $-92.56 Million | -0.495x | +32.58% |
| 2014-12-31 | $100.48 Million | $-73.74 Million | -0.734x | -133.00% |
| 2013-12-31 | $186.29 Million | $-58.67 Million | -0.315x | +17.45% |
| 2012-12-31 | $114.83 Million | $-43.81 Million | -0.382x | +19.12% |
| 2011-12-31 | $99.88 Million | $-47.12 Million | -0.472x | +52.15% |
| 2010-12-31 | $52.11 Million | $-51.37 Million | -0.986x | +81.27% |
| 2009-12-31 | $6.38 Million | $-33.55 Million | -5.262x | -399.07% |
| 2008-12-31 | $16.16 Million | $-17.04 Million | -1.054x | -28.81% |
| 2007-12-31 | $39.13 Million | $-32.03 Million | -0.819x | -73.81% |
| 2006-12-31 | $79.07 Million | $-37.24 Million | -0.471x | -53.22% |
| 2005-12-31 | $74.36 Million | $-22.86 Million | -0.307x | -151.02% |
| 2004-12-31 | $59.88 Million | $-7.33 Million | -0.122x | -148.62% |
| 2003-12-31 | $-57.20 Million | $-14.41 Million | 0.252x | -0.60% |
| 2002-12-31 | $-56.37 Million | $-14.28 Million | 0.253x | -- |
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more